Beijing Hotgen Biotech Co., Ltd.
Location
Beijing
Founded
2005-10-23
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., In Vitro and In Vivo Diagnostic Substances), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Beijing Hotgen Biotech Co., Ltd.
Live alerts from global media, monitored by Business Radar
2025-03-08 (cnfol.com)
Rejing Bio (688068.SH): Bioinnovative drugs and tumor early screening and other related businesses are independently operated by associates_Individual Stock Information_Market_CICC Online
Zhitong Finance APP News Rejing Bio 688068 SH issued an announcement on stock price abnormality, saying that the company's current main business is R&D, production and sales of in vitro diagnostic reagents and supporting instruments, and related businesses such as innovative drugs and tumor screening are independently operated by the company's associate companies Shunjing Pharmaceutical Yaojing Gene Zhiyuan Bio and Aoru Bio. The related businesses have large R&D investment and R&D style.
Read more
2024-11-22 (businessupturn.com)
Stock Market news : Wuhan Golden Laser Leads Gainers with 20.03% Rise; Beijing Hotgen Biotech Drops 9.59%
Wuhan Golden Laser surged 20.03% to 14.92 CNY, topping the gainers, while Beijing Hotgen Biotech led losses, declining 9.59% to 45.84 CNY amid mixed market performance.
Read more